Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AmBisome and DaunoXome Approved in Switzerland BOULDER, Colo.-- Jan. 7, 1997--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that the Swiss Ministry of Health has approved separately AmBisome and DaunoXome. The Company will launch both drugs in Switzerland shortly. The Swiss Ministry approved AmBisome, the Company's liposomal antifungal drug, for the treatment of severe blood-borne fungal infections in patients where amphotericin B was insufficiently effective or who suffer from kidney damage. Twenty-five countries have now approved AmBisome for use in treating life-threatening fungal infections. In the United States, NeXstar Pharmaceuticals and marketing partner Fujisawa USA submitted a wide-ranging New Drug Application in November 1996. DaunoXome, the Company's liposomal anticancer agent, was approved as a first-line therapy for the treatment of HIV-associated Kaposi's sarcoma, a form of cancer that largely affects HIV-positive homosexual men. DaunoXome is now approved in 16 countries, including the United States. The Company is conducting additional clinical trials to test DaunoXome's use as a therapy for lymphoma, breast cancer and other cancers. Liposomes are microscopic fat bubbles that can be used to encase a drug. NeXstar Pharmaceuticals has developed liposomes that specifically target the delivery of the drug to disease or infection in the body. AmBisome is the only true liposomal form of amphotericin B, a potent but toxic antifungal agent, approved for clinical use. DaunoXome's liposomal formulation of the anticancer drug daunorubicin is designed to maximize the selectivity of daunorubicin for solid tumors in the body. NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases, including cancer and infectious diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder, Colo.; research, development and manufacturing facilities in San Dimas, Calif.; Lakewood, Colo., and Boulder; and marketing subsidiaries worldwide. E-mail this page to a friend or colleague! To print, use this version